Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more

3rd June 2021

Pharmanovia Promotes Alessandro Insalata to Chief Commercial Officer

Basildon (UK), 3 June 2021 – Pharmanovia, the original medicines specialist globally announced the promotion of...

More information
3rd May 2021

The Original Medicines Specialist Rebrands to Pharmanovia

Basildon (UK), 4 May 2021 – Atnahs, the original medicines specialist backed by PE investor Triton Partners,...

More information
22nd March 2021

Atnahs Appoints New Chief Financial Officer

Basildon (UK), 22 March 2021 – Atnahs has appointed Felipe Florez to the position of Chief Financial...

More information
1st December 2020

Atnahs Acquires Rights to Valium®

Basildon (UK), 1 December 2020 – Atnahs (“Atnahs”), has acquired the commercial rights for Valium® (Diazepam) in...

More information
19th March 2020

COVID-19: Atnahs Continues Operations

Basildon (UK), 19 March 2020  – On 11 March 2020 the World Health Organization (WHO) declared...

More information
19th March 2020

Atnahs Acquires Rights to Rocaltrol®, An Established Brand in Women’s Health

Basildon (UK) / Basle (Switzerland), 19 March 2020 – Atnahs (“Atnahs”), a Triton Fund V portfolio company,...

More information
6th February 2020

Atnahs Buys Takeda Out of License Agreement for Bonviva® in Asia

Basildon (UK), 6 February 2020 – Atnahs has bought Takeda out of a license agreement for...

More information
27th January 2020

Atnahs Acquires Rights to Established Hypertension Medicines

Basildon / Cambridge (UK), 27 January 2020 – Atnahs, a Triton Fund V portfolio company, has signed...

More information
8th August 2019

Triton Completes Acquisition of a Majority Stake in Atnahs

Frankfurt (Germany), Basildon (United Kingdom), August 8, 2019 – Funds advised by Triton have successfully completed...

More information